HilleVax, Inc., (HLVX): Price and Financial Metrics
GET POWR RATINGS... FREE!
HLVX Stock Price Chart Interactive Chart >
HLVX Price/Volume Stats
| Current price | $15.06 | 52-week high | $24.42 |
| Prev. close | $15.78 | 52-week low | $7.90 |
| Day low | $15.05 | Volume | 28,300 |
| Day high | $16.10 | Avg. volume | 34,311 |
| 50-day MA | $16.43 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 502.18M |
HilleVax, Inc., (HLVX) Company Bio
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Latest HLVX News From Around the Web
Below are the latest news stories about HILLEVAX INC that investors may wish to consider to help them evaluate HLVX as an investment opportunity.
HilleVax Announces Executive Management Appointments and PromotionsBOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Ozzie Berger as Senior Vice President of Regulatory Affairs, the promotion of Anju Chatterji to Chief Technical Officer, and the promotion of Shane Maltbie to Chief Financial Officer. As part of a planned transition in connection with Mr. Maltbie’s promotion, David Socks will focus on busin |
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gast |
HilleVax, Boston’s biggest IPO of 2022, wants to end common norovirus effectJust nine IPOs were recorded among Boston-area companies in 2022, after more than two dozen went public in 2021. In fact, 10 IPOs last year raised more money than this year's largest, HilleVax. Here's the infection Hillevax hopes to tackle. |
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
HLVX Price Returns
| 1-mo | -9.98% |
| 3-mo | -29.56% |
| 6-mo | 28.39% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -9.98% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...